ANNX — Annexon, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1528115 ·
Last close
$5.31
Market Cap
$870.00M
52W High
$6.61
52W Low
$4.78
ADV30
2,169,657
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,053,000 | -44,142,000 | 262,888,000 | 175,208,000 | 58,355,000 |
| Dec 2025 | 0 | — | -50,258,000 | -48,256,000 | 277,571,000 | 162,051,000 | 65,923,000 |
| Sep 2025 | 0 | — | -57,018,000 | -54,922,000 | 229,142,000 | 139,419,000 | 67,700,000 |
| Jun 2025 | 0 | — | -51,726,000 | -49,156,000 | 264,573,000 | 132,288,000 | 65,556,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,356,000
Investing CF
$190,052,000
Financing CF
$108,855,000
CapEx
$-143,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-917,389,000
Inventory
—
Receivables
—
ST Investments
$76,294,000
EBIT TTM
$-216,407,000
Pretax Income TTM
$-206,690,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -216,407,000 | -206,690,000 | 277,571,000 | 65,923,000 | — | -186,356,000 |
| Dec 2024 | 0 | -154,073,000 | -138,200,000 | 350,071,000 | 56,966,000 | — | -118,006,000 |
| Dec 2023 | 0 | -143,723,000 | -134,237,000 | 297,674,000 | 47,118,000 | — | -121,142,000 |
| Dec 2022 | 0 | -145,599,000 | -141,947,000 | 285,096,000 | 53,902,000 | — | -116,309,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.92
Max Pain — expiry 2026-07-17
max pain strike: $4.00 · spot: $5.52 · call oi: 5,689 · put oi: 237
Expected Move to 2026-07-17:
±$1.27
(23.10%) —
implied range
$4.24 –
$6.79
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | $871.90M | $13.30 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $861.27M | $8.32 | — |
| AVTX | Avalo Therapeutics, Inc. | $859.45M | $16.35 | — |
| ABUS | Arbutus Biopharma Corp | $859.29M | $4.35 | — |
| JANX | Janux Therapeutics, Inc. | $885.49M | $14.52 | — |
News headlines (Yahoo Finance, 1h cache)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 20:05 · Yahoo
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
2026-05-14 08:05 · Yahoo
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
2026-05-11 14:00 · Yahoo
Exploring 3 High Growth Tech Stocks In The US Market
2026-05-11 11:38 · Yahoo
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
2026-05-07 20:01 · Yahoo
Annexon to Present at the Bank of America Securities Health Care Conference 2026
2026-05-06 12:00 · Yahoo
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
2026-04-27 06:22 · Yahoo
Annexon Biosciences (ANNX) Buy Rating Retained
2026-04-21 21:14 · Yahoo
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
2026-04-15 21:02 · Yahoo
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.